Home › Research › Risk factors
HIV-associated nephropathy
Michael J. Ross, Paul E. Klotman. AIDS, 2004-05-01
Topic: Risk, prevention and care in population studies
The high prevalence of injecting drug use among affected patients prompted some authors to conclude that concurrent heroin nephropathy, not HIV-1 infection per se, was responsible for this renal syndrome. As a result, HIV-associated nephropathy (HIVAN) became recognized as a separate entity and soon was found to be the most common cause of chronic renal failure and end stage renal disease (ESRD) in HIV-1 infected patients [5,6]. Despite the presence of proteinuria that is often in the nephrotic range, most patients with HIVAN do not have significant peripheral edema [15]. These observations, coupled with the finding that HIV-seropositive patients often have a decreased ability to conserve sodium [17] suggest that HIVAN may be a salt-wasting disease. Serologic studies are usually negative although a significant percentage of HIV-1 seropositive patients are co-infected with hepatitis C virus (HCV) [18]. Since firmly establishing the diagnosis of HIVAN versus a different renal disease is important to guide treatment and provides prognostic information, clinicians should have a low threshold for obtaining renal biopsies in HIV-1-seropositive patients with significant proteinuria and/or renal insufficiency. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the US Government.As a result of the decline in mortality from AIDS, however, the number of black patients who are living with HIV infection or AIDS has increased dramatically (Fig. 3) [23]. Though this study did not specify the types of renal disease, the presence of renal disease was disproportionately higher in black (11.9%) compared to white patients (3.3%), suggesting that a this difference (8.6%) may reflect underlying HIVAN. Recently, published data from the HIV Epidemiology Research Study Group revealed that among HIV-1 seropositive women (without AIDS), 7.2% had renal abnormalities (defined as serum creatinine > 1.4 mg/dl or > 2+ proteinuria on urinary dipstick) at baseline. Furthermore, after adjusting for multiple comorbidities, the presence of renal disease was with a increased risk of death While the of HIVAN has been studied in the it is to be most in the more than living with HIV/AIDS nearly in the prevalence of HIVAN among is similar to that among African there are and cases of HIVAN in this Despite these however, there is a of published data the of HIVAN in for These include a of a fai
Key findings
- The high prevalence of injecting drug use among affected patients prompted some authors to conclude that concurrent heroin nephropathy, not HIV-1 infection per se, was responsible for this renal syndrome.
- As a result, HIV-associated nephropathy (HIVAN) became recognized as a separate entity and soon was found to be the most common cause of chronic renal failure and end stage renal disease (ESRD) in HIV-1 infected patients [5,6].
- Despite the presence of proteinuria that is often in the nephrotic range, most patients with HIVAN do not have significant peripheral edema [15].
- These observations, coupled with the finding that HIV-seropositive patients often have a decreased ability to conserve sodium [17] suggest that HIVAN may be a salt-wasting disease.
- Serologic studies are usually negative although a significant percentage of HIV-1 seropositive patients are co-infected with hepatitis C virus (HCV) [18].
Why it matters
This article describes HIV-associated nephropathy, a kidney disease in people with HIV, and does not address Alzheimer's disease at all. It provides no information relevant to treating, curing, or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Participants200
- Effect size3.5%; 11.9%; 3.3%
- Evidence strengthModerate
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 45 of the 97 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (AIDS) |
| Journal's citation record | 3 / 4 | AIDS: journal h-index 267 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2004 — older than 20 years, still counted |
| Sample size | 2 / 4 | 200 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 78 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.2 citations a year over 24 year(s) since 2004 |
| Impact for its field and year | 3 / 6 | Cited 5.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Paul E. Klotman: h-index 65 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 15166524) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 45 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 97 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Ross, M. J., & Klotman, P. E. (2004). HIV-associated nephropathy. AIDS. https://doi.org/10.1097/00002030-200405210-00002
Vancouver
Ross MJ, Klotman PE. HIV-associated nephropathy. AIDS. 2004. doi:10.1097/00002030-200405210-00002. PMID: 15166524.
BibTeX
@article{ross2004-15166524,
author = {Ross, Michael J. and Klotman, Paul E.},
title = {{HIV-associated nephropathy}},
journal = {AIDS},
year = {2004},
doi = {10.1097/00002030-200405210-00002},
pmid = {15166524},
url = {https://doi.org/10.1097/00002030-200405210-00002}
}